The Idiopathic Intracranial Hypertension Treatment Trial
Michael Wall(Dudley Group NHS Foundation Trust), Michael McDermott(Unknown), Karl Kieburtz(Beth Israel Deaconess Medical Center), Eleanor Schron(National Institutes of Health), Steven E. Feldon(University of Rochester Medical Center), Mark J. Kupersmith(New York Eye and Ear Infirmary), James J. Corbett(Wellington Hospital), Deborah I. Friedman(Texas Neurology), John L. Keltner(Washington University in St. Louis), David M. Katz(University Hospitals of Cleveland)
Cited by 475
Related Papers
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
|New England Journal of Medicine|1992|1.3k
Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
|Arthritis & Rheumatism|2004|743
Interleukin-1–Receptor Antagonist in the Muckle–Wells Syndrome
|New England Journal of Medicine|2003|655